Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach.

Jennifer L Lund Michael A Webster-ClarkSharon Peacock HintonShahar Shmuel Til StürmerHanna K Sanoff

Published in: Pharmacoepidemiology and drug safety (2020)

This study supports mounting evidence of little to no incremental reduction in 5-year mortality for FOLFOX vs 5FU in older adults with stage II-III colon cancer, emphasizing the importance of combining clinical trial and real-world data to support such conclusions.

Keyphrases

clinical trial
randomized controlled trial
metastatic colorectal cancer
systematic review
early stage
physical activity
cardiovascular events
big data
community dwelling
cardiovascular disease
type diabetes
artificial intelligence
data analysis